phosphoribosyl pyrophosphate and trimetrexate

phosphoribosyl pyrophosphate has been researched along with trimetrexate in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (33.33)	18.7374
1990's	2 (66.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bertino, JR; Colofiore, JR; Li, WW; Romanini, A	1
Dykes, DJ; Elliott, WL; Howard, CT; Leopold, WR	1
André, M; Bertino, JR; Conti, JA; Goker, E; Kemeny, N; Ragusa, K; Seiter, K; Tong, W	1

Trials

1 trial(s) available for phosphoribosyl pyrophosphate and trimetrexate

Article	Year
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Phosphoribosyl Pyrophosphate; Survival Analysis; Treatment Outcome; Trimetrexate	1994

Article

Year

Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:4

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Phosphoribosyl Pyrophosphate; Survival Analysis; Treatment Outcome; Trimetrexate

1994

Other Studies

2 other study(ies) available for phosphoribosyl pyrophosphate and trimetrexate

Article	Year
Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. Journal of the National Cancer Institute, 1992, Jul-01, Volume: 84, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Humans; Leucovorin; Leukemia, Lymphoid; Methotrexate; Phosphoribosyl Pyrophosphate; Trimetrexate; Tumor Cells, Cultured	1992
Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer research, 1989, Oct-15, Volume: 49, Issue:20 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Cricetinae; Drug Administration Schedule; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Leukemia P388; Mice; Phosphoribosyl Pyrophosphate; Quinazolines; Trimetrexate	1989

Article

Year

Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.

Journal of the National Cancer Institute, 1992, Jul-01, Volume: 84, Issue:13

Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Humans; Leucovorin; Leukemia, Lymphoid; Methotrexate; Phosphoribosyl Pyrophosphate; Trimetrexate; Tumor Cells, Cultured

1992

Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.

Cancer research, 1989, Oct-15, Volume: 49, Issue:20

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Cricetinae; Drug Administration Schedule; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Leukemia P388; Mice; Phosphoribosyl Pyrophosphate; Quinazolines; Trimetrexate

1989